AUSTRALIAN researchers in Melbourne and China have used experimental drugs to target a recently described molecular pathway that damages the brain after a stroke, bringing these treatments one step closer to the clinic for stroke sufferers.
Using pre-clinical animal models of ischaemic stroke, researchers have now shown that the tau protein, which stabilises the cellular 'train track' that transports molecules around cells, is also involved in stroke.
Published in Molecular Psychiatry, the study showed that tau levels could be protected following a stroke and five different experimental drugs were trialled, with ferroptosis inhibitors clear winners for their therapeutic potential in the end.
Visit nature.com for the study.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Sep 17